NurExone Biologic Inc.
NRXBF
$0.40
$0.000.40%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.24% | 9.77% | -17.20% | -39.32% | -82.00% |
| Total Depreciation and Amortization | 30.23% | 35.90% | 161.11% | 223.08% | 186.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.21% | 8.41% | 4.11% | -2.19% | 1,204.17% |
| Change in Net Operating Assets | -90.48% | 65.60% | -298.98% | 247.54% | 157.73% |
| Cash from Operations | -25.35% | 32.33% | -56.97% | -22.64% | 32.70% |
| Capital Expenditure | 93.75% | 80.43% | 96.01% | 96.72% | 86.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 93.75% | 80.00% | 96.01% | 97.18% | 86.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -166.67% | -42.86% | 0.00% | 85.71% | 62.50% |
| Issuance of Common Stock | -30.67% | 56.30% | -- | 10,506.67% | -79.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -31.32% | 1,183.62% | -15.65% | 3,513.64% | -79.31% |
| Foreign Exchange rate Adjustments | -275.00% | 130.00% | -450.00% | 340.74% | -118.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -460.71% | 163.36% | -277.54% | 173.56% | -104.13% |